- Ipsogen Luminy Biotech Entreprises Case 923 - 163, Avenue de Luminy 13288 France
Ipsogen has introduced BCR-ABL Mbcr IS-MMR kits, to enable standardisation of BCR-ABL Mbcr quantification by calibrating each result to the International Scale, providing accurate results.
Ipsogen, a molecular diagnostic company specialising in diagnostic assays for breast cancer and leukaemia, has announced the European launch of the Mapquant Dx HR test.
Ipsogen has announced the CE marking of its Profilequant WT1 kit.
Ipsogen has announced that Helene Peyro-Saint-Paul has joined the company as chief medical officer.
Ipsogen, a cancer profiler that markets molecular diagnostic assays for leukemia and breast cancer, has announced the European launch of Mapquant DX Her2 test.